Shuguang Yuan

Co-founder at AlphaMol Science Ltd

Speaker

Dr. Shuguang Yuan finished his doctoral dissertation which was funded by the Maria Curia Fellowship. It was conducted in three different institutes in Europe: EPFL(Switzerland), Polish Academy of Science (Poland) and KULeuven University (Belgium).

In his research, he investigated mainly the molecular mechanism of G protein-coupled receptors (GPCRs). In June 2013, he was awarded with a PhD title with the honor of distinguished thesis. Following that, he was offered the Marie Curie ETH Postdoc Fellowship. In 2014, Dr. Yuan proposed a theory about the activation mechanism and the continuous water channel of GPCRs, which can be used to differentiate different functional molecules.

Dr Yuan worked at Idorsia (previously known as Actelion) Pharmaceutical Ltd in Basel as a specialist in computer-aided drug design (CADD) for 5 years. In the past few years, he has advanced two of his designed molecules into clinical trials.

In 2021, Dr. Yuan successfully led his team joint the Global GPCR-DOCK 2021 contest. The team of Dr. Yuan had been ranked as top1 in KOR-peptide predictions. The overall accuracy was 60% higher than Google's AlphaFold2 and 100% higher than RosettaFold. In 02.2025, Dr. Yuan led his team to obtain IND approval from American FDA for their first-in-class dual functional molecule against MRGPRX2 receptor.